1. Market Research
  2. > Neurodegenerative Diseases – Pipeline Review, H1 2013

Neurodegenerative Diseases – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 228 pages

Neurodegenerative Diseases – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Neurodegenerative Diseases - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neurodegenerative Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurodegenerative Diseases. Neurodegenerative Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neurodegenerative Diseases.
- A review of the Neurodegenerative Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neurodegenerative Diseases pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neurodegenerative Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neurodegenerative Diseases pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Neurodegenerative Diseases - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Neurodegenerative Diseases Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Neurodegenerative Diseases 11
Neurodegenerative Diseases Therapeutics under Development by Companies 13
Neurodegenerative Diseases Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Neurodegenerative Diseases Therapeutics - Products under Development by Companies 25
Neurodegenerative Diseases Therapeutics - Products under Investigation by Universities/Institutes 31
Companies Involved in Neurodegenerative Diseases Therapeutics Development 33
Bristol-Myers Squibb Company 33
F. Hoffmann-La Roche Ltd. 34
Biogen Idec Inc. 35
Apotex, Inc. 36
ExonHit Therapeutics SA 37
Isotechnika Pharma Inc. 38
EnVivo Pharmaceuticals 39
Pfizer Inc. 40
Merck KGaA 41
Addex Pharmaceuticals 42
Proneuron Biotechnologies, Inc. 43
American Biogenetic Sciences, Inc. 44
Genfit 45
Nymox Pharmaceutical Corporation 46
ACADIA Pharmaceuticals Inc. 47
Yungjin Pharm Ind. Co., Ltd. 48
WhanIn Pharmaceutical Co., Ltd. 49
Suven Life Sciences Ltd. 50
MediPost Co., Ltd. 51
Santhera Pharmaceuticals Holding AG 52
NatureWise Biotech and Medicals Corp 53
Mithridion, Inc. 54
SCYNEXIS, Inc. 55
Chipscreen Biosciences Ltd 56
Sirtris Pharmaceuticals, Inc. 57
Wellstat Therapeutics Corporation 58
Celon Pharma Sp. z o.o. 59
Aegera Therapeutics Inc. 60
AngioChem Inc. 61
Phoenix Biotechnology, Inc. 62
Antyra, Inc. 63
TetraLogic Pharmaceuticals 64
Neurimmune Therapeutics AG 65
PsychoGenics, Inc. 66
ALS Therapy Development Institute 67
GenKyoTex S.A. 68
Affichem 69
NeuroNascent, Inc. 70
Siena Biotech S.p.A. 71
NovaLead Pharma Pvt. Ltd. 72
Acetylon Pharmaceuticals, Inc. 73
N-Gene Research Laboratories, Inc. 74
BT PHARMA 75
Nexgenix Pharmaceuticals, LLC 76
Proteostasis Therapeutics, Inc. 77
Encore Therapeutics Inc. 78
ArmaGen Technologies, Inc. 79
Ausio Pharmaceuticals, LLC 80
Errant Gene Therapeutics, LLC 81
Varinel, Inc. 82
Sigmoid Pharma. 83
Socratech, L.L.C. 84
Neurodegenerative Diseases - Therapeutics Assessment 85
Assessment by Monotherapy Products 85
Assessment by Route of Administration 86
Assessment by Molecule Type 88
Drug Profiles 90
EVP-0334 - Drug Profile 90
G-15750 - Drug Profile 92
TGFTX-1 Program - Drug Profile 93
TGFTX-3 Program - Drug Profile 94
CSO-240-0600 - Drug Profile 95
NeuroTrans Program - Drug Profile 96
NXD-5150 - Drug Profile 97
NNI-370 - Drug Profile 98
AF-243 - Drug Profile 99
Necrostatin Program - Drug Profile 100
AUS-131 - Drug Profile 101
EHT/AGN-0002 - Drug Profile 103
VAR-10300 - Drug Profile 104
EPO Mimetics - Drug Profile 106
AMT-090 - Drug Profile 107
NXD-30001 - Drug Profile 108
PN-277 - Drug Profile 110
VAR-10100 - Drug Profile 111
VAR-10200 - Drug Profile 112
AGT-110 - Drug Profile 113
idebenone - Drug Profile 114
MTP-131 - Drug Profile 117
ANG-3101 - Drug Profile 119
ANG-3201 - Drug Profile 120
AGT-115 - Drug Profile 121
EHT/AGN-0003 - Drug Profile 122
uridine triacetate - Drug Profile 123
Immunoglobulin - Drug Profile 125
NLP-61 - Drug Profile 126
YJP-60107 - Drug Profile 127
NST-0005 - Drug Profile 128
rifampin - Drug Profile 129
NG-094 - Drug Profile 130
Cyclophilin D Inhibitors - Drug Profile 131
FRP-XX - Drug Profile 132
AF-250s - Drug Profile 133
Alpha Synuclein Program - Drug Profile 134
Tau Program - Drug Profile 135
TDP-43 Program - Drug Profile 136
NOX 2/1 Inhibitors - Drug Profile 137
NT-KO-003 - Drug Profile 138
SRT-3025 - Drug Profile 140
P2X7 Compounds - Drug Profile 142
TRKB PAM - Drug Profile 143
SUVN-507 - Drug Profile 144
SUVN-901 - Drug Profile 145
SUVN-976 - Drug Profile 146
SUVN-G1010034 - Drug Profile 147
Drug Acting On Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 For Neuro Degenerative Diseases - Drug Profile 148
SUVN-D1108121 - Drug Profile 149
ER-Beta Program - Drug Profile 150
PT-00114 - Drug Profile 151
PT-00311 - Drug Profile 152
Glutaminyl Cyclase Inhibitors - Drug Profile 153
NST-0060 - Drug Profile 154
NPS-0155 - Drug Profile 155
FRP-924 - Drug Profile 156
PBI-04711 - Drug Profile 157
NT-KO-009 - Drug Profile 158
NT-KO-012 - Drug Profile 159
NT-CC-017 - Drug Profile 160
F-637 - Drug Profile 161
ABS-205 - Drug Profile 162
WIN-1001X - Drug Profile 163
GSK-3beta Inhibitor - Drug Profile 164
RDC-5 - Drug Profile 165
Program 3 - Drug Profile 167
JRP-655 - Drug Profile 168
PPLs - Drug Profile 169
MAC-i Class I - Drug Profile 170
MAC-i Class II - Drug Profile 171
CPN-9 - Drug Profile 172
EAB-318 - Drug Profile 173
NI-205 - Drug Profile 174
HSP90 Inhibitors - Drug Profile 175
NICAM Program - Drug Profile 176
MI-08-016/035 - Drug Profile 178
CS-410 - Drug Profile 179
meldonium - Drug Profile 180
Caffeic Acid Phenethyl Ester - Drug Profile 181
TDI-185 - Drug Profile 182
Hsp90 Inhibitors - Drug Profile 183
Stem Cells For Neurogenesis - Drug Profile 184
Adenosine Antagonists - Drug Profile 185
miR-29b - Drug Profile 186
Histone Deacetylase Inhibitors - Drug Profile 187
Estrogen Receptor Ligand - Drug Profile 188
ABHxD-I - Drug Profile 189
Enreptin - Drug Profile 190
RNAi For Trinucleotide Repeat Diseases - Drug Profile 191
RE-024 - Drug Profile 192
TrkB Agonists - Drug Profile 193
Gamma-Secretase Modulators - Drug Profile 194
Retinal Neuroprotective Compounds - Drug Profile 195
Drug For Neuroprotection And Neurite-Promoting Activity - Drug Profile 196
UBP-608 - Drug Profile 197
CDNF Protein Therapy For Other Neurodegenerative Disease - Drug Profile 198
Neurodegenerative Diseases Therapeutics - Drug Profile Updates 199
Neurodegenerative Diseases Therapeutics - Discontinued Products 210
Neurodegenerative Diseases Therapeutics - Dormant Products 211
Neurodegenerative Diseases - Product Development Milestones 215
Featured News and Press Releases 215
Appendix 220
Methodology 220
Coverage 220
Secondary Research 220
Primary Research 220
Expert Panel Validation 220
Contact Us 221
Disclaimer 221

List of Tables

Number of Products Under Development for Neurodegenerative Diseases, H1 2013 18
Products under Development for Neurodegenerative Diseases - Comparative Analysis, H1 2013 19
Number of Products under Development by Companies, H1 2013 21
Number of Products under Development by Companies, H1 2013 (Contd..1) 22
Number of Products under Development by Companies, H1 2013 (Contd..2) 23
Number of Products under Development by Companies, H1 2013 (Contd..3) 24
Number of Products under Development by Companies, H1 2013 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2013 27
Comparative Analysis by Late Stage Development, H1 2013 28
Comparative Analysis by Mid Clinical Stage Development, H1 2013 29
Comparative Analysis by Early Clinical Stage Development, H1 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 31
Products under Development by Companies, H1 2013 32
Products under Development by Companies, H1 2013 (Contd..1) 33
Products under Development by Companies, H1 2013 (Contd..2) 34
Products under Development by Companies, H1 2013 (Contd..3) 35
Products under Development by Companies, H1 2013 (Contd..4) 36
Products under Development by Companies, H1 2013 (Contd..5) 37
Products under Investigation by Universities/Institutes, H1 2013 38
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 39
Bristol-Myers Squibb Company, H1 2013 40
F. Hoffmann-La Roche Ltd., H1 2013 41
Biogen Idec Inc., H1 2013 42
Apotex, Inc., H1 2013 43
ExonHit Therapeutics SA, H1 2013 44
Isotechnika Pharma Inc., H1 2013 45
EnVivo Pharmaceuticals, H1 2013 46
Pfizer Inc., H1 2013 47
Merck KGaA, H1 2013 48
Addex Pharmaceuticals, H1 2013 49
Proneuron Biotechnologies, Inc., H1 2013 50
American Biogenetic Sciences, Inc., H1 2013 51
Genfit, H1 2013 52
Nymox Pharmaceutical Corporation, H1 2013 53
ACADIA Pharmaceuticals Inc., H1 2013 54
Yungjin Pharm Ind. Co., Ltd., H1 2013 55
WhanIn Pharmaceutical Co., Ltd., H1 2013 56
Suven Life Sciences Ltd., H1 2013 57
MediPost Co., Ltd., H1 2013 58
Santhera Pharmaceuticals Holding AG, H1 2013 59
NatureWise Biotech and Medicals Corp, H1 2013 60
Mithridion, Inc., H1 2013 61
SCYNEXIS, Inc., H1 2013 62
Chipscreen Biosciences Ltd, H1 2013 63
Sirtris Pharmaceuticals, Inc., H1 2013 64
Wellstat Therapeutics Corporation, H1 2013 65
Celon Pharma Sp. z o.o., H1 2013 66
Aegera Therapeutics Inc., H1 2013 67
AngioChem Inc., H1 2013 68
Phoenix Biotechnology, Inc., H1 2013 69
Antyra, Inc., H1 2013 70
TetraLogic Pharmaceuticals, H1 2013 71
Neurimmune Therapeutics AG, H1 2013 72
PsychoGenics, Inc., H1 2013 73
ALS Therapy Development Institute, H1 2013 74
GenKyoTex S.A., H1 2013 75
Affichem, H1 2013 76
NeuroNascent, Inc., H1 2013 77
Siena Biotech S.p.A., H1 2013 78
NovaLead Pharma Pvt. Ltd., H1 2013 79
Acetylon Pharmaceuticals, Inc., H1 2013 80
N-Gene Research Laboratories, Inc., H1 2013 81
BT PHARMA, H1 2013 82
Nexgenix Pharmaceuticals, LLC, H1 2013 83
Proteostasis Therapeutics, Inc., H1 2013 84
Encore Therapeutics Inc., H1 2013 85
ArmaGen Technologies, Inc., H1 2013 86
Ausio Pharmaceuticals, LLC, H1 2013 87
Errant Gene Therapeutics, LLC, H1 2013 88
Varinel, Inc., H1 2013 89
Sigmoid Pharma., H1 2013 90
Socratech, L.L.C., H1 2013 91
Assessment by Monotherapy Products, H1 2013 92
Assessment by Stage and Route of Administration, H1 2013 94
Assessment by Stage and Molecule Type, H1 2013 96
Neurodegenerative Diseases Therapeutics - Drug Profile Updates 206
Neurodegenerative Diseases Therapeutics - Discontinued Products 217
Neurodegenerative Diseases Therapeutics - Dormant Products 218
Neurodegenerative Diseases Therapeutics - Dormant Products (Contd..1) 219
Neurodegenerative Diseases Therapeutics - Dormant Products (Contd..2) 220
Neurodegenerative Diseases Therapeutics - Dormant Products (Contd..3) 221

List of Figures

Number of Products under Development for Neurodegenerative Diseases, H1 2013 18
Products under Development for Neurodegenerative Diseases - Comparative Analysis, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Investigation by Universities/Institutes, H1 2013 26
Late Stage Products, H1 2013 28
Mid Clinical Stage Products, H1 2013 29
Early Clinical Stage Products, H1 2013 30
Discovery and Pre-Clinical Stage Products, H1 2013 31
Assessment by Monotherapy Products, H1 2013 92
Assessment by Route of Administration, H1 2013 93
Assessment by Stage and Route of Administration, H1 2013 94
Assessment by Molecule Type, H1 2013 95
Assessment by Stage and Molecule Type, H1 2013 96

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.